Nanoscope to Submit Biologics License Application in 2025

Nanoscope Therapeutics Inc., a late-stage biotech company focused on gene therapies for retinal diseases, announced a productive FDA meeting regarding MCO-010 for retinitis pigmentosa (RP). Following FDA feedback, Nanoscope plans to start a Biologics License Application (BLA) submission in Q1 2025, utilizing a rolling submission process supported by MCO-010’s Fast Track Designation for treating severe vision loss in RP.

Learn more